New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation

Cytokine

Volumn 59, Issue 3, 2012, Pages 451-459

  Bamias, Giorgos ^a,c   Corridoni, Daniele ^a   Pizarro, Theresa T ^a,b   Cominelli, Fabio ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cytokines; Inflammatory bowel disease; Interleukins; Intestinal inflammationl; TNF superfamily

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; CYTOKINE; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 33; INTERLEUKIN 36; PROTEIN TL1A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ARTHRITIS; CHRONIC INFLAMMATION; COLITIS; CROHN DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE EXACERBATION; ENTERITIS; GENETIC DISORDER; GUT MUCOSAL HOMEOSTASIS; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSORIASIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; ULCERATIVE COLITIS;

ANIMALS; CYTOKINES; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; INFLAMMATION; INTESTINAL MUCOSA;

EID: 84864993041     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.014     Document Type: Review

References (102)

1. Flavell R. Cytokines in health and disease. J Med Sci 2008, 1(1):26-28.
2. Pizarro T.T., Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med 2007, 58:433-444.
3. Olson T.S., et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 2006, 203(3):541-552.
4. Pagnini C., et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 2010, 107(1):454-459.
5. Pizarro T.T., et al. Mouse models for the study of Crohn's disease. Trends Mol Med 2003, 9(5):218-222.
6. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20:495-549.
7. Lees C.W., et al. New IBD genetics: common pathways with other diseases. Gut 2011, 60(12):1739-1753.
8. Shih D.Q., Targan S.R., McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 2008, 10(6):568-575.
9. Clemente J.C., et al. The impact of the gut microbiota on human health: an integrative view. Cell 2012, 148(6):1258-1270.
10. Round J.L., O'Connell R.M., Mazmanian S.K. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010, 34(3):J220-J225.
11. Mazmanian S.K., Round J.L., Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453(7195):620-625.
12. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009, 9(11):799-809.
13. Oppenheim J.J., et al. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003, 62(Suppl 2):ii17-ii21.
14. Macpherson A.J., et al. The immune geography of IgA induction and function. Mucosal Immunol 2008, 1(1):11-22.
15. Kelsall B.L. Innate and adaptive mechanisms to control [corrected] pathological intestinal inflammation. J Pathol 2008, 214(2):242-259.
16. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474(7351):298-306.
17. Cominelli F. Cytokine-based therapies for Crohn's disease-new paradigms. N Engl J Med 2004, 351(20):2045-2048.
18. Arseneau K.O., et al. Innate and adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep 2007, 9(6):508-512.
19. Bamias G., Kaltsa G., Ladas S.D. Cytokines in the pathogenesis of ulcerative colitis. Discov Med 2011, 11(60):459-467.
20. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361(21):2066-2078.
21. Cho J.H., Brant S.R. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011, 140(6):1704-1712.
22. Werts C., et al. Nod-like receptors in intestinal homeostasis, inflammation, and cancer. J Leukoc Biol 2011, 90(3):471-482.
23. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009, 43:67-93.
24. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447(7145): 661-78.
25. Cadwell K., et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008, 456(7219):259-263.
26. Cooney R., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010, 16(1):90-97.
27. Kaser A., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134(5):743-756.
28. Ferretti M., et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994, 94(1):449-453.
29. Cominelli F., et al. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992, 103(1):65-71.
30. Cominelli F., et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990, 86(3):972-980.
31. Cominelli F., et al. Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest 1990, 85(2):582-586.
32. Jacobs C., et al. In vivo treatment with IL-1 reduces the severity and duration of antigen-induced arthritis in rats. J Immunol 1988, 141(9):2967-2974.
33. van der Meer J.W., et al. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 1988, 85(5):1620-1623.
34. Kojouharoff G., et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997, 107(2):353-358.
35. Bohan A., et al. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003, 278(38):36688-36698.
36. Naito Y., et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 2003, 18(5):560-569.
37. Mizoguchi E., et al. TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology 2008, 134(2):470-480.
38. Ebach D.R., Newberry R., Stenson W.F. Differential role of tumor necrosis factor receptors in TNBS colitis. Inflamm Bowel Dis 2005, 11(6):533-540.
39. Ebach D.R., Riehl T.E., Stenson W.F. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock 2005, 23(4):311-318.
40. Zheng L., et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377(6547):348-351.
41. Zhou T., et al. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996, 156(8):2661-2665.
42. Noti M., et al. TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 2010, 207(5):1057-1066.
43. Pizarro T.T., et al. SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis 2011, 17(12):2566-2584.
44. Nenci A., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007, 446(7135):557-561.
45. Gong J., et al. Epithelial-specific blockade of MyD88-dependent pathway causes spontaneous small intestinal inflammation. Clin Immunol 2010, 136(2):245-256.
46. Asquith M.J., et al. Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease. Gastroenterology 2010, 139(2):519-529. [529 e1-2].
47. Rakoff-Nahoum S., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118(2):229-241.
48. Tebbutt N.C., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002, 8(10):1089-1097.
49. Reuter B.K., Pizarro T.T. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?. Eur J Immunol 2004, 34(9):2347-2355.
50. Takagi H., et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol 2003, 38(8):837-844.
51. Zaki M.H., et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32(3):379-391.
52. Pizarro T.T., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999, 162(11):6829-6835.
53. Bamias G., et al. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Dig Liver Dis 2012, 44(1):30-36.
54. Bamias G., et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 2010, 137(2):242-249.
55. Bamias G., et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003, 171(9):4868-4874.
56. Hsu H., Viney J.L. The tale of TL1A in inflammation. Mucosal Immunol 2011, 4(4):368-370.
57. Meylan F., Richard A.C., Siegel R.M. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev 2011, 244(1):188-196.
58. Bamias G., et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 2006, 103(22):8441-8446.
59. Prehn J.L., et al. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 2007, 178(7):4033-4038.
60. Saruta M., et al. TLR8-mediated activation of human monocytes inhibits TL1A expression. Eur J Immunol 2009, 39(8):2195-2202.
61. Shih D.Q., et al. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 2009, 39(11):3239-3250.
62. Shih D.Q., et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One 2011, 6(1):e16090.
63. Taraban V.Y., et al. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 2011, 4(2):186-196.
64. Meylan F., et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol 2011, 4(2):172-185.
65. Sarra M., et al. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 2010, 16(10):1808-1813.
66. O'Connor W., et al. A protective function for interleukin-17A in T cell-mediated intestinal inflammation. Nat Immunol 2009, 10(6):603-609.
67. Wolk K., et al. Biology of interleukin-22. Semin Immunopathol 2010, 32(1):17-31.
68. Seidelin J.B., et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 2010, 128(1):80-85.
69. Beltrán C.J., et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010, 16(7):1097-1107.
70. Pastorelli L., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010, 107(17):8017-8022.
71. Kobori A., et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastronterol 2010, 45(10):999-1007.
72. Schmitz J., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5):479-490.
73. Smithgall M.D., et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20(8):1019-1030.
74. Xu D., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008, 105(31):10913-10918.
75. Palmer G., et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60(3):738-749.
76. Delaney P et al. unpublished results; 2012.
77. Duan L et. al IL-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) Treg responses in mice. Mol Med. 2012. 10.2119/molmed.2011.00428. [Epub ahead of print].
78. Grob P., et al. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 2012, 10.1002/ibd.22900.
79. Vigne S., et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118(22):5813-5823.
80. van de Veerdonk F.L., et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA 2012, 109(8):3001-3005.
81. McNamee E.N., et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 2012, 108(40):16711-16716.
82. Bamias G., et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005, 128(3):654-666.
83. Kugathasan S., et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007, 56(12):1696-1705.
84. Spencer D.M., et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002, 122(1):94-105.
85. Holland S.M. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010, 38(1):3-10.
86. Marks D.J., et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 2009, 104(1):117-124.
87. Dieckgraefe B.K., et al. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002, 161(Suppl 1):S88-S92.
88. Visser G., et al. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European study on glycogen storage disease type 1. Eur J Pediatr 2002, 161(Suppl 1):S83-S87.
89. Yu J.E., et al. High levels of Crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease. Clin Immunol 2011, 138(1):14-22.
90. Visser G., et al. Intestinal function in glycogen storage disease type I. J Inherit Metab Dis 2002, 25(4):261-267.
91. Davis M.K., et al. Antibodies to CBir1 are associated with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr 2010, 51(1):14-18.
92. Alsultan A., et al. Long term G-CSF-induced remission of ulcerative colitis-like inflammatory bowel disease in a patient with glycogen storage disease Ib and evaluation of associated neutrophil function. Pediatr Blood Cancer 2010, 55(7):1410-1413.
93. Marks D.J., et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006, 367(9511):668-678.
94. Smith A.M., et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009, 206(9):1883-1897.
95. Valentine J.F., et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut 2009, 58(10):1354-1362.
96. Korzenik J.R., et al. Sargramostim for active Crohn's disease. N Engl J Med 2005, 352(21):2193-2201.
97. van Dijken T.D., et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011, 38(7):1441-1446.
98. Toussirot E., et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease A nationwide series. Joint Bone Spine 2011, 67:990.
99. Guerra I., et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2011.
100. Cullen G., et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011, 34(11-12):1318-1327.
101. Ramji A., et al. Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance?. Dig Dis Sci 2002, 47(3):522-527.
102. Halim M.A., et al. De novo Crohn's disease in a renal transplant recipient. Transplant Proc 2007, 39(4):1278-1279.